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Abstract
Introduction: Hemophilia is uncommon in females and there is little knowledge about the clinical
manifestation.
Case presentation: We report here an unusual case of three hemophilic females diagnosed as
factor IX deficient. Normal reports of ultrasonography (USG) and relevant endocrine investigations
conducted in two adult females ruled out any usual gynecological and endocrinal causes of bleeding.
Complete coagulation profiles were conducted and diagnosed these female bleeders to be
hemophiliacs suffering from factor IX deficiency.
Conclusion: Females presenting with menorrhagia and bleeding from other sites without any
discernable cause require proper evaluation for congenital coagulation disorders. In the present case
series, females are diagnosed factor IX deficient (Hemophilia B).
Introduction
Menorrhagia is a frequent clinical manifestation of several
rare congenital disorders of blood coagulation and
platelets [1]. Women with heavy menstruation might not
seek medical advice due to unawareness hence the
objective assessment of menstrual loss is must-using
Pictorial Blood Assessment Chart (PBAC). Usually, 40%
of women with losses greater than 80 ml may consider
their period as moderate or scanty, conversely, 60% of
women with losses <20 ml may consider their period as
“heavy”. Universally, menstrual blood losses >80 ml is
considered as heavy bleeding, therefore, PBAC with semi
quantitative assessment of blood losses method adopted
to assess the real and false menorrhagia. Awareness in
clinicians is also required as menorrhagia is a common
problem in women with inherited bleeding disorder and
that can be presenting symptom. Hemophilia B is X linked
bleeding disorder caused by partial or complete deficiency
or dysfunction of factor IX resulting from a variety of
defects in the FIX gene [2]. Hemophilia B is reported to
affect 1 in 1,00,000 male births in the U.S. and 1 in 30,000
males birth in UK [3]. while, prevalence and morbidity in
females with menorrhagia in inherited bleeding disorders
have been poorly investigated. Currently 40% to 60%
menstruating women complain of menorrhagia with a
significant impact on their quality of life, estimated to be
of type 1 or 2 and more than 60% of women with type 3
vonWillebrand Disease [4]. In cases, where there is no
family history of the disorder the condition is the result of
a spontaneous gene mutation. Factor IX deficiency is
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[3]. Generally the presenting symptoms by patients
suffering from hemophilia B is bruising, spontaneous
bleeding, bleeding into joints associated pain with
swelling and hemorrhage in gastrointestinal tract and
urinary tract leading to blood in the urine or stool,
prolonged bleeding after injury, tooth extraction, and
surgery. Biochemical and Pathological examination in
present study done for jaundice, other signs of liver failure
(e.g. cirrhosis from viral infection), and of opportunistic
infections in patients who are HIV seroconverted to rule
out other cause of menorrhagia. No secondary acquired
cause of bleeding found. The screening and diagnostic test
based upon abnormal Activated Partial Thromboplastin
Time, its correction study and factor assay with deficient
plasma/serum and severe factor IX deficient plasma used
for factor level assays [5]. Normal prothrombin time (PT)
and abnormal activated partial thromboplastin time
(APTT) ruled out the other vitamin K dependent disorder
and common pathway defect.
Case presentation
Case report 1
An Aryan Hindu 33-year’s-old Indian married woman,
complained menorrhagia since last eight years. She could
not assess herself to be heavy bleeder therefore; she went
to her family gynecologist to have her view regarding the
inconvenience she was facing from the last eight years. The
ultrasonography (USG) and relevant endocrine investi-
gations revealed no hemorrhagic ovarian cysts or endome-
triosis, which may also be the common causes of bleeding
in women. She has neither the family history of bleeding
nor she herself bleed from any other site. Reference sent to
our lab for complete coagulation profile. Pictorial blood
assessment chart (PBAC) with semi quantitative assess-
ment of blood losses method adopted to assess the real
and false menorrhagia. Monthly assessment revealed
flooding of blood for more than 80 ml. Screening test
resulted in normal prothrombin time (PT), platelet counts
(P/C) and function, fibrinogen and thrombin time (TT)
with prolonged activated partial thromboplastin time
(APTT). This indicated intrinsic pathway defect and ruled
out deficiency of vitamin K and Factor V. Mixing study
(diagnostic test) showed deficiency of factor IX and the
factor assay revealed 42% factor IX activity level (mild
deficiency) (Table 1).
Case report 2
An Arabian origin Muslim young unmarried Indian,
18-year’s-old girl gave the history of prolonged gum
bleeding, epistaxis along with the history of menorrhagia
since menarche. She was not suffering from any gyneco-
logical problem. Nasal examination by ENT surgeon and
gum bleeding examined by dental specialist disclosed no
primary cause of bleeding from the effective site. She was
born of consanguineous marriage, but having no family
history of bleeding. Monthly assessment using PBAC
showed bleeding more than 90 ml. Patient approached
us for complete coagulation profile. Screening test
revealed only abnormal APTT indicative of intrinsic
pathway defect. Mixing study resulted in deficiency of
factor IX. Factor assay revealed 37% factor IX activity level
(mild deficiency) (Table 1).
Case report 3
An Aryan Hindu infant 3-year’s-old Indian girl presented
with off and on petachae and echymotic patches all over
body, followed by epistaxis since one year. Nasal
Table 1.
Case No. Screening test Diagnostic test correction study Factor IX
assay
Fibrinogen*
(normal range
200-400 mg/dl) Mix of normal pool plasma
& test plasma (1.1)
Mix of Factor VIII def.
plasma and test plasma
(1.1)
Mix of Factor IX def.
plasma and test plasma
(1.1)
PT
(sec)
APTT
(sec)
TT
(sec)
APTT (sec) APTT (sec) APTT (sec)
Case 1 C:14 C:24 C:10 26 28 68 42% 288 mg/dl
T:14 T:52 T:11
Case 2 C:14 C:28 C:10 28 28 82 37% 310 mg/dl
T:14 T:68 T:11
Case 3 C:14 C:24 C:10 25 30 140 26% 325 mg/dl
T:14 T:85 T:12
Remarks Raised APTT indicates intrinsic pathway defect Correction of APTT with normal plasma and FVIII def. plasma and no correction
with FIX def. plasma indicates absence of inhibitor & def. of factor IX.
Abbreviations: APTT, activated partial thromboplastin time; def, deficient/deficiency; Mix, mixture; PT, prothrombin time; TT, thrombin time. The method
used for PT, APTT, TT, and fibrinogen was manual technique using commercial reagent (from Diagnostic Stago) as described by Pitney & Brozovic [5].
* The method used for factor IX assay, was manual technique using commercial factor VIII and IX deficient plasma (from Diagnostic Stago) and as described
by Pitney & Brozovic [5] (Semi quantitative assay).
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of bleeding from the effective site. There was no family
history of bleeding. Then the reference reached coagula-
tion lab for analyzing coagulation disorder. Screening test
as above revealed intrinsic pathway defect. Mixing study
and factor assay revealed deficiency of factor IX with 26%
of factor IX activity level (mild deficiency).
Discussion
All the three patients had Liver Function Test report
normal (already done from biochemistry laboratory)
indicating that patient does not have any acquired
conditions causing factor IX deficiency. Further, a normal
prothrombintestvalueinscreeningtestruledoutvitaminK
deficiency and vitamin K dependent factor deficiency.
None of the three patients received any treatment without
prior diagnosis. After detection of the deficiency; the factor
IX concentrates infused to replace the defective clotting
factor. This normalized the uncontrolled bleeding and
improved the hemoglobin condition in all the three cases.
Like other parts, haemostatic plugs also characterize
homeostasis in the endometrium and more important
role it plays during first 2-3 days of menstruation. Studies
reported high prevalence of menorrhagia among females
with von Willebrand disease [6]. Factor IX, a vitamin
K-dependent single-chain glycoprotein, synthesized first
by the hepatocyte as a precursor protein (protein in
vitamin K absence); then, it undergoes extensive post-
translational modification to become the fully gamma-
carboxylated mature zymogens and secreted finally into
the blood [2]. The g-carboxylation of nearly all of the 12
amino-terminal glutamic residues is most important, since
this modification is required for calcium ion binding and
full enzymatic activity [7]. A 3-fold variation in the activity
of factor IX in plasma is normal. Since factor IX is smaller
than albumin, it distributes in both the extra vascular and
intra vascular compartments [2]. Characterization of a
young female with mild hemophilia B is a novel missense
mutation (codon 351, GCT (Ala) → CCT (Pro) of the FIX
gene [8]. Menorrhagia therefore, a life threatening hidden
disorder can be unusually due to severe and unexpected
inherited bleeding disorder with a very high mortality rate
if unchecked needs precise screening of coagulation
disorder. The study indicates the method of analyzing
heavy uterine bleeding and emphasize on screening of
coagulation disorder.
Conclusion
Since substantial number of women complains for
menorrhagia after menarche irrespective of their age,
therefore investigation of such patients for inherited
bleeding disorders before planning for any therapy or
undergoing invasive procedures: hysteroscopy and
hysterectomy that may lead to a high rate of postoperative
bleeding is of utmost importance.
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